- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04084080
낫적혈구병 및 CardiovAscular 위험 - 적혈구 교환 시험(SCD-CARRE) (SCD-CARRE)
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
연구 개요
상세 설명
As patients with sickle cell disease (SCD) live to adulthood, the chronic impact of sustained hemolytic anemia and episodic vaso-occlusive events take their toll, with the progressive development of cardiopulmonary organ dysfunction. This culminates in the development of pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, chronic kidney disease and sudden death, all major cardiovascular complications of SCD for which there are no approved or consensus therapies. The risk of having pulmonary hypertension and diastolic heart disease can be non-invasively assessed by laboratory tests (NT-proBNP) and Doppler-echocardiography (estimated pulmonary artery systolic pressure). A recent meta-analysis of approximately 6000 patients with SCD demonstrated that patients with elevated tricuspid regurgitant jet velocity (TRV), which is an Doppler-echocardiographic measurement that estimates the pulmonary artery systolic pressure, walked an estimated 30.4 meters less in a 6 minute walk test than those without elevated TRV, and elevated TRV was associated with high mortality (hazard ratio of 4.9). In two large registry cohorts of adult patients with SCD, the investigators found that approximately 20% of the adult SCD population have high values for both biomarkers, defined as a TRV ≥ 2.5 meters per second AND a NT-proBNP ≥ 160 pg/mL, and that the 12-month mortality rate is 7.9% in this group as compared to 0.5% in patients with normal TRV or NT-proBNP values, with a risk ratio for hospitalization of 1.6. This suggests that a simple screening profile of TRV and NT-proBNP can identify about 20% of patients with SCD at the highest risk of death and hospitalization.
Given the increased mortality and early loss of functional capacity associated with cardiovascular disease in SCD adults, it is important to test effective therapeutic interventions in such patients. Red blood cell transfusions are administered by either simple or exchange transfusion, the latter removes the patients blood and replaces it with transfused red blood cells. Exchange transfusions have proven effective for acute treatment of almost all SCD complications, including severe acute chest syndrome, stroke, splenic or hepatic sequestration, and multi-organ failure, and are also used chronically for stroke prevention and recurrent acute chest syndrome. In this study the investigators hypothesize that monthly exchange transfusion will limit disease progression, improve exercise capacity, and prevent interval episodes of vaso-occlusive painful crisis and the acute chest syndrome that acutely increases pulmonary pressures and cause right heart failure.
The investigators propose to perform a clinical trial to evaluate the effects of automated exchange blood transfusion on patient morbidity and mortality, compared to standard of care among 150 adult high risk SCD patients. The trial will leverage existing coordinating center infrastructure at the University of Pittsburgh and will involve 22 experienced clinical sites. Despite the safety and wide utilization of erythrocytapheresis in adult patients with SCD, there is no consensus or quality efficacy data on its use to improve outcomes in our aging high-risk SCD patients with progressive end-organ dysfunction.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Tuscaloosa, Alabama, 미국, 35401
- University of Alabama
-
-
California
-
Oakland, California, 미국, 94609
- UCSF Benioff Children's Hospital Oakland
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20060
- Howard University Center for Sickle Cell Disease
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, 미국, 60607
- University of Illinois at Chicago
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- University of Maryland
-
Baltimore, Maryland, 미국, 21206
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02118
- Boston Medical Center
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University-St. Louis
-
-
New York
-
New York, New York, 미국, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, 미국, 10461
- Montefiore Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, 미국, 28204
- Atrium Health
-
Durham, North Carolina, 미국, 27708
- Duke University
-
Greenville, North Carolina, 미국, 27834
- East Carolina University
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- University Hospitals Cleveland Medical Center
-
Columbus, Ohio, 미국, 43210
- Ohio State University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- University of Pittsburgh Medical Center
-
-
Texas
-
Houston, Texas, 미국, 77030
- University of Texas Health Science Center at Houston
-
-
Virginia
-
Richmond, Virginia, 미국, 23284
- Virginia Commonwealth University
-
-
-
-
-
Rio de Janeiro, 브라질
- Hemorio
-
-
-
-
-
Créteil, 프랑스
- Kremlin-Bicêtre
-
Paris, 프랑스
- Henri Mondor Hopital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age 18 years or older
-
Diagnosis of SCD: homozygous sickle cell disease, hemoglobin-SC, Sβ-thalassemia, hemoglobin-SO or hemoglobin-SD.
-
Patients not on a chronic exchange transfusion program for at least 60 days.
-
If patients are on a SCD drug (e.g. hydroxyurea, glutamine, or P-selectin inhibitors), the doses must be stable for at least 60 days prior to randomization. At the time of randomization, participants must be off Oxbryta for at least 30 days.
-
Any one of the following vasculopathy biomarker clinical results (a, b, c, d or e) measured in the last 24 months before randomization that indicates a high-risk patient:
- Both a TRV 2.5- <3.0 m/sec and NT-proBNP plasma level ≥ 160 pg/mL,
- TRV ≥ 3.0 m/sec,
- Both a mean pulmonary artery pressure (PAP) by right heart catheterization 20-24 mmHg and NT-proBNP plasma level ≥ 160 pg/mL,
- Mean PAP by right heart catheterization ≥ 25 mmHg,
- Chronic kidney disease (CKD) due to SCD with abnormal measures on 2 separate occasions as defined by: macroalbuminuria (albumin to creatinine ratio (ACR) >300 mg/g) or proteinuria (protein to creatinine ratio >30 mg/mmol), or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. (It is recommended that local laboratories use Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation without ethnic factors when estimating and reporting GFR).
Clinical results of these biomarkers measured locally at sites within 24 months prior to randomization are acceptable to determine eligibility. TRV, PAP, NT-proBNP, albumin to creatinine ratio, protein to creatinine ratio, or eGFR values must be measured in a steady state (defined as measured ≥ 14 days since an acute care pain event) on different days.
vi. Written informed consent obtained from patient to participate in the trial.
Exclusion Criteria:
- RBC alloimmunization resulting in inability of blood bank to obtain compatible components for chronic exchange transfusions
- Previous history of hyper-hemolysis syndrome
- Previous history of severe transfusion reaction resulting in renal failure or due to serious complications such as hypotension or respiratory distress
- More than 10 vaso-occlusive episodes in the past 12 months requiring admission to a hospital to receive treatment.
- Religious objection to receiving blood transfusion
- Diagnosis of ischemic stroke within the past 6 months
- Clinical evidence of liver failure or advanced cirrhosis or any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the trial
- Women of childbearing potential who have a positive pregnancy test at baseline
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Exchange transfusion plus standard of care
Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months. |
Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of <20% and a pre-transfusion hemoglobin S of <30%.
다른 이름들:
NHLBI/ASH/ATS Expert Panel recommended guidelines |
|
활성 비교기: Standard of care
Randomized to standard of care |
NHLBI/ASH/ATS Expert Panel recommended guidelines |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Episodes of clinical worsening
기간: 13 months
|
The efficacy of the intervention will be measured by comparing the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 13 months between groups. |
13 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Acute healthcare event
기간: 13 months
|
A 6-level prioritized rank-based outcome: 1.No death or SCD-related acute health care encounters (SCDAcuteE) within (w/in) 13 months (m) of randomization; 2. Had SCDAcuteE but NO major complications (acute kidney injury (AKI), acute chest syndrome (ACS), cor pulmonale, stroke, liver failure) associated with an SCDAcuteE nor death w/in 13 m of randomization; 3. Had 1 major complication (AKI, ACS, cor pulmonale, stroke, or liver failure) associated with an SCDAcuteE but not death w/in 13 m of randomization; 4. Had 2 major complications (AKI, ACS, cor pulmonale, stroke, or liver failure) associated with SCDAcuteE but not death w/in 13 m of randomization; 5. Had ≥ 3 major complications (AKI, ACS, cor pulmonale, stroke, or liver failure) associated with SCDAcuteE but not death w/in 13 m of randomization; 6.Death w/in 13 m of randomization. If the same complication reoccurs, occurrences will be counted as separate complications if the acute health care encounters are separated by ≥7 days. |
13 months
|
|
Twelve-month survival
기간: 13 months
|
Survival over thirteen-month period will be analyzed and compared between the group receiving the intervention and the group receiving care routinely provided for sickle cell patients based on the NHLBI guidelines. |
13 months
|
|
Survival free of acute healthcare encounters
기간: 13 months
|
Survival free of acute health care encounters over 13 months. |
13 months
|
|
Total number of acute health care encounters
기간: 13 months
|
The total number of acute health care encounters (non-elective infusion center/ER/Hospital visits) with evidence of cor pulmonale (physical exam findings, NT-proBNP increase plus echocardiographic evidence of worsening right heart function). |
13 months
|
|
Measures of exercise capacity - 6 minute walk distance
기간: 4, 8, and 12 months
|
Measures of exercise capacity assessed at 4, 8 and 12 months by the distance walked in the six minute walk distance assessment |
4, 8, and 12 months
|
|
Measures of exercise capacity - outpatient activity
기간: 4, 8, and 12 months
|
Measures of exercise capacity assessed at 4, 8 and 12 months by the distance walked in a 7 day in the outpatient setting. |
4, 8, and 12 months
|
|
Cardiovascular risk
기간: 12 months
|
Established cardiovascular risk biomarkers and indices are combined to help the investigators form an opinion about cardiovascular risks. The following will be measured: NT-proBNP, QT prolongation, systemic pulse pressure, albuminuria, estimated GFR and CKD progression Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group criteria. |
12 months
|
|
Development of new leg ulcers
기간: 4, 8 and 12 months
|
Participants will be assessed for development of new leg ulcers at each physical exam. |
4, 8 and 12 months
|
|
Measures of exercise capacity - WHO Classification
기간: 4, 8 and 12 months
|
WHO functional status severity will be measured assessing by looking at limitation of usual physical activity from I (no limitation in usual physical activity) to Class IV (inability to perform any physical activity at rest) |
4, 8 and 12 months
|
|
Nocturnal desaturation
기간: 4, 8 and 12 months
|
Nocturnal desaturation will measured using a wearable device to measure blood oxygen saturation for 7 nights at home. |
4, 8 and 12 months
|
|
SCD specific patient reported outcomes - Pain
기간: 4, 8 and 12 months
|
SCD specific patient reported outcomes as measured by self-reported pain |
4, 8 and 12 months
|
|
SCD specific patient reported outcomes -Quality of Life modified PROMIS scale
기간: 4, 8 and 12 months
|
SCD specific patient reported outcomes as measured by a modified version of health related quality of life questionnaire from PROMIS QoL measure |
4, 8 and 12 months
|
|
SCD specific patient reported outcomes -Quality of Life modified ASCQ-Me scale
기간: 4, 8 and 12 months
|
SCD specific patient reported outcomes as measured by a modified version of health related quality of life questionnaire from ASCQ-Me QoL measure |
4, 8 and 12 months
|
|
Cardiovascular function by echocardiography - TRV
기간: 4, 8 and 12 months
|
Cardiovascular function measures from echocardiography assessed at 4, 8 and 12 months: echocardiographic measures of tricuspid regurgitant jet velocity in m/s. |
4, 8 and 12 months
|
|
Cardiovascular function by echocardiography - diastolic left heart function
기간: 4, 8 and 12 months
|
Diastolic left heart function measured by E/A ratio, E/Em ratio, and deceleration times will be assessed by echocardiography. |
4, 8 and 12 months
|
|
Cardiovascular function by echocardiography - systolic right heart function
기간: 4, 8 and 12 months
|
Systolic right heart health will be measured by assessing tricuspid annular plane systolic excursion (TAPSE), right ventricular size and contractility from echocardiography of the heart. |
4, 8 and 12 months
|
|
Total number of acute health care encounters
기간: 13 months
|
The number of acute health care encounters (non-elective infusion center/ER/Hospital visits) with at least one major complication. |
13 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Maria Brooks, PhD, University of Pittsburgh
- 연구 의자: Mark Gladwin, MD, University of Maryland
- 수석 연구원: Darrell Triulzi, MD, University of Pittsburgh
간행물 및 유용한 링크
일반 간행물
- Abbasi M, Srivastava A, Saraf SL. Management of Kidney Disease with Sickle Cell Disease. J Am Soc Nephrol. 2025 Oct 1;36(10):2041-2054. doi: 10.1681/ASN.0000000804. Epub 2025 Jun 26.
- Bertolet M, Triulzi DJ, Campbell-Lee S, Gordeuk VR, Herbert BM, Novelli E, Jonassaint C, Villanueva F, Chien N, Gladwin MT, Brooks MM; SCD-CARRE Investigators. Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial. Am Heart J. 2026 Jul 15;301:107542. doi: 10.1016/j.ahj.2026.107542. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- STUDY20110362
- UG3HL143192 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Results from research conducted under this project will be shared in several ways. Manuscripts will be submitted for publication in high-quality peer-reviewed journals, following the NIH Public Access Policy guidelines. Findings will be presented at relevant national conferences, public lectures, scientific institutions and meetings. The timeline for participant recruitment, data collection and analysis will foster publication, facilitated by the investigators' Publications Committee, of critically important and clinically relevant data throughout the trial. The study datasets will be archived and made available to qualified individuals after a period of exclusive use by the SCD-CARRE trial research team and after publication of the primary manuscripts, following NIH guidelines.
IPD 공유 기간
At the end of the trial, study de-identified datasets will be submitted for permanent archive in the NHLBI BioLINCC repository. The trial will also produce deliverables that will be freely available to the sickle cell community including a description of the protocol for automated red blood cell exchange transfusion.
IPD 공유 액세스 기준
All publications based on the SCD-CARRE trial will adhere to the NIH Public Access Policy (Notice NOT-OD-08-033). All study data will be de-identified. At the end of the trial, study de-identified datasets will be submitted for permanent archive in the NHLBI BioLINCC repository.
The investigators also will work closely with regional and National SCD Foundations to promote recruitment for this study and communicate our results.
IPD 공유 지원 정보 유형
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .